(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -38.43% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Arvinas's revenue in 2026 is $316,700,000.On average, 17 Wall Street analysts forecast ARVN's revenue for 2026 to be $7,804,495,758, with the lowest ARVN revenue forecast at $3,379,158,351, and the highest ARVN revenue forecast at $13,253,127,054. On average, 17 Wall Street analysts forecast ARVN's revenue for 2027 to be $4,457,180,482, with the lowest ARVN revenue forecast at $1,589,603,689, and the highest ARVN revenue forecast at $8,630,323,350.
In 2028, ARVN is forecast to generate $5,807,405,326 in revenue, with the lowest revenue forecast at $2,170,690,769 and the highest revenue forecast at $13,546,057,189.